Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
(Date:6/30/2015)... SAN DIEGO , June 30, 2015 /PRNewswire/ ... Continuing Education in Biosciences (CCE/Bio) and UC San ... microbial fermentation, to be held Aug.  12 – ... agenda ).  This three-day workshop provides an intense ... in industrial biotechnology, and is well-suited to biologists, ...
(Date:6/30/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... focused on the development of autologous cell therapies, announced ... 1/2 clinical trial of RCT-01, being tested for ... been enrolled and their tissue biopsy sent for ... comprised of non-bulbar dermal sheath (NBDS) cells isolated ...
Breaking Biology Technology:New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... WI Aug. 11 Sonic Foundry a rich media ... Distance Teaching and Learning will use its Mediasite Live ... addresses and panel presentations, and make them available on-demand ... conference proceedings. , ,Held Aug. 13-15 at the Monona ...
... week a leading information technology publication named four traditional ... work in IT. All four placed in the top ... higher than MasterCard, Wal-Mart, Ford, and UPS. American Family ... was ranked 40. What do all of these companies ...
... MADISON, Wis Small and mid-sized business in the ... a new alliance announced today between Wisconsin Manufacturing ... Consortium for Global e-Commerce (UW CGEC) which will ... Wisconsin manufacturers apply e-business technologies to supply chain ...
Cached Biology Technology:Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand 2Dynamics of Wisconsins Real-Time Economy Part 3 2Alliance Brings E-Business Technologies to Wisconsin Manufacturers 2
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market announces that its Wocket® smart wallet will ... the Mark", scheduled to air on WABC Radio (am770) in ... . The broadcast air- time for the ... EST. NXT-ID, Inc.,s CEO Gino Pereira will be ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... with Yale University and the Denver Crime Lab report in ... cancer,s ability to fuse with blood cells in a way ... cancer cells to enter the bloodstream and seed sites of ... a bone marrow transplant patient with cancer, along with DNA ...
... puzzle pieces scattered across a football field, with too ... the picture. Scientists in the new but fast-growing ... In recent decades, these researchers have begun to assemble ... animals, plants and microbes, unlocking a door that will ...
... 2013 Dr. Jeffrey Trent, President and Research Director ... state-of-the-art genomics research July 16 at the Brookings Institution. ... Director of the National Human Genome Research Institute, is ... 2nd annual State of Biomedical Innovation Conference, which will ...
Cached Biology News:CSI-style DNA fingerprinting tracks down cause of cancer spread 2Solving DNA puzzles is overwhelming computer systems, researchers warn 2Solving DNA puzzles is overwhelming computer systems, researchers warn 3TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... is the smallest electronic pressure controller available ... Parker configured this unit specifically for the ... Used in carrier gas flow control, microfluidic ... and hydro-dynamic focusing, the OEM-EPC offers external ...
... Thrust Slide is designed for heavy duty ... limited and substantial side-loading is present. Standard ... millions of trouble-free cycles even in high ... or recirculating ball bearings , Optional corrosion ...
Biology Products: